Magnolia Capital Advisors’s Gilead Sciences GILD Stock Holding History

Magnolia Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$382K	Sell	3,020 -300	-9%	-$39.5K	0.07%	224
2026 Q1	$463K	Buy	3,320 +34	+1%	+$4.76K	0.09%	209
2025 Q4	$403K	Buy	3,286 +190	+6%	+$23.1K	0.08%	203
2025 Q3	$344K	Buy	3,096 +29	+0.9%	+$3.3K	0.09%	183
2025 Q2	$340K	Buy	3,067 +33	+1%	+$3.51K	0.09%	188
2025 Q1	$340K	Sell	3,034 -223	-7%	-$23K	0.09%	181
2024 Q4	$301K	Buy	+3,257	New	+$293K	0.08%	194
2022 Q2	–	Sell	-3,481	Closed	-$207K	–	150
2022 Q1	$207K	Buy	3,481 +241	+7%	+$15.4K	0.08%	177
2021 Q4	$235K	Buy	+3,240	New	+$223K	0.07%	176

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Magnolia Capital Advisors's GILD Position: Q2 2026 in Review

Magnolia Capital Advisors reduced its Gilead Sciences (GILD) stake by 9% in Q2 2026, selling an estimated $39.5K and leaving 3,020 shares worth $382K. The position accounts for 0.07% of the portfolio, ranked #224.

Magnolia Capital Advisors first reported a position in GILD in Q4 2021 and has held it in 9 quarters since. The position peaked at $463K in Q1 2026. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Magnolia Capital Advisors held 3,020 shares of Gilead Sciences worth $382K as of Q2 2026.
Magnolia Capital Advisors sold 300 Gilead Sciences shares in Q2 2026, an estimated $39.5K.
Gilead Sciences made up 0.07% of Magnolia Capital Advisors's portfolio in Q2 2026, its #224 holding.
Magnolia Capital Advisors first reported a position in Gilead Sciences in Q4 2021 and has held it in 9 quarters since.
Magnolia Capital Advisors's Gilead Sciences position peaked at $463K in Q1 2026.
2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Magnolia Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.